1 BAG. Prä- und post-expositionelle Tollwutprophylaxe beim Menschen, Bundesamt für Gesundheit, Arbeitsgruppe Tollwut, Schweizerische Kommission für Impffragen, Juli 2004.
2 Cramer JP, Jelinek T, Paulke-Korinek M, Reisinger EC, Dieckmann S, Alberer M, et al. One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series. J Travel Med. 2016;23(3):pii:taw011.
3 WHO Expert Consultation on Rabies. WHO Technical Report Series 1012, April 2018.
4 WHO. Rabies vaccines: WHO position paper – WER No 16, 20 April 2018.
5 De Pijper CA, Boersma J, Terryn S, Van Gucht S, Goorhuis A, Grobusch MP, Stijnis C. Rabies antibody response after two intradermal perexposure prophylaxis immunizations: An observational cohort study. Trav Med and Inf Dis. 2018;22:36–9.
6 Siegrist CA. Vaccine Immunology, Chapter 2, in: Plotkin’s Vaccines, 7th edition 2018.
7 Strady C Andreoletti L, Baumard S, Servettaz A, Jaussaud R, Strady A. Immunogenicity and booster efficacy of pre-exposure rabies vaccination. Trans R Soc Trop Med Hyg. 2009;103(11):1159–64.